TIMP3 as a VEGF Inhibitor

Angiogenesis is the process of new blood vessel formation from pre-existing ones. Vascular endothelial growth factor (VEGF) can induce angiogenesis and vascular leakage in the eye, which can lead to retinal diseases. The present invention relates to the use of peptides comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) to substantially inhibit VEGF binding to VEGF receptor-2, while not inhibiting VEGF binding to VEGF receptor 1. This has applications for Age-Related Macular Degeneration, tumor growth, and Sorsby’s Fundus Dystrophy. Patents are issued. Peptide has been identified. Torey Hovest hovestt@ccf.org 216-445-5431

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More